InMed Pharmaceuticals Reports Positive Preclinical Data for INM-901 Alzheimer’s Program

Vancouver, BC – March 23, 2026 – InMed Pharmaceuticals Inc. (NASDAQ: INM) has announced significant new preclinical results supporting its INM-901 drug candidate for Alzheimer’s disease. The company’s pipeline focuses on disease-modifying small molecule drugs targeting CB1 and CB2 receptors, and these latest findings may be highly relevant for investors seeking exposure to innovative neurology therapeutics.

Key Highlights

• Positive Preclinical Data: INM-901 demonstrated consistent, dose-dependent anti-neuroinflammatory effects in advanced 3D human brain organoid models. These models are among the closest approximations to human brain tissue currently available, incorporating neurons, astrocytes, vascular cells, and microglia—the brain’s immune cells.
• Translation from Animal to Human Systems: The studies, conducted in collaboration with Stem Pharm, Inc., bridge the gap between previous animal model results and human-relevant tissue systems, significantly de-risking the INM-901 program ahead of first-in-human clinical trials.
• Reduction of Pro-inflammatory Markers: INM-901 reduced key pro-inflammatory markers (IL-6 and IL-8) in both general and Alzheimer’s disease-specific organoid models. These effects align with prior in vivo and ex vivo findings, further validating the compound’s mechanism.
• Mechanistic Consistency: Across multiple preclinical platforms—including long-term mouse models and ex vivo neuroinflammation models—INM-901 consistently reduced inflammatory biomarkers (IFN-γ, TNF-α, IL-1β, KC-GRO, IL-2, NfL) and demonstrated anti-inflammatory effects independent of amyloid-beta or tau pathology.

Potentially Price-Sensitive Information

• De-risking of Clinical Development: The translation of anti-inflammatory effects into human brain organoids is a critical milestone, significantly reducing clinical risk and boosting confidence in INM-901’s potential efficacy for neuroinflammatory conditions, including Alzheimer’s disease.
• Upcoming Regulatory Milestones: InMed plans to conduct a pre-IND (Investigational New Drug) meeting with the FDA in Q3/2026, continue IND-enabling pharmacology and toxicology studies, and scale up drug manufacturing. The company is targeting IND submission and initiation of a Phase 1 clinical trial in 2027.
• Strategic Shift in Alzheimer’s Drug Development: With recent focus shifting from amyloid and tau pathology to neuroinflammation as a driver of disease progression, INM-901 is well-positioned as a next-generation therapeutic candidate. This could attract investor interest given the limitations of current Alzheimer’s treatments.

Why This Matters for Shareholders

The consistent validation of INM-901’s anti-neuroinflammatory action across animal, ex vivo, and now advanced human brain organoid models is a substantial development. It strengthens the scientific rationale for the program and could accelerate regulatory and clinical progress, potentially increasing the company’s valuation. Shareholders should note that successful translation into human systems is a major risk reduction ahead of clinical trials—a factor that could influence share price upon positive future regulatory or clinical updates.

Next Steps for INM-901 Program

• Pre-IND meeting with FDA slated for Q3 2026.
• Continued IND-enabling studies in pharmacology and toxicology.
• Scale-up of manufacturing activities to support clinical development.
• Engagement with regulatory and clinical experts to finalize trial design.
• Targeting IND submission and Phase 1 trial initiation in 2027.

About InMed Pharmaceuticals

InMed Pharmaceuticals develops proprietary small-molecule drug candidates targeting CB1/CB2 receptors. The pipeline includes treatments for Alzheimer’s, ocular, and dermatological indications.

About Stem Pharm, Inc.

Stem Pharm’s drug discovery platform uses human 3D neuro-immune organoids to model neuroinflammation, aiding target discovery for Alzheimer’s, epilepsy, and brain cancer.

Investor Contact

Colin Clancy, Vice President, Investor Relations and Corporate Communications
Phone: +1.604.416.0999
Email: [email protected]

Disclaimer: This article contains forward-looking statements based on current expectations, subject to risks and uncertainties that may cause actual results to differ materially. Investors are advised to review InMed’s filings with the SEC for a comprehensive discussion of risk factors. This is not investment advice. InMed disclaims any obligation to update forward-looking statements except as required by law.

View InMed Pharmaceuticals Inc. Historical chart here